Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALL

Anita Rijneveld • 20 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Anita Rijneveld, MD, Erasmus MC, Rotterdam, Netherlands, gives recommendations on the use of blinatumomab and inotuzumab ozogamicin in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). According to Dr Rijneveld, patients who have central nervous system (CNS) involvement or patients with high tumor burden and high white blood cell count should be treated with inotuzumab ozogamicin, whilst patients at high risk of veno-occlusive disease (VOD), patients undergoing a second transplant, or elderly and heavily pre-treated patients should receive blinatumomab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding from Servier and Amgen

More from Anita Rijneveld

The key unmet needs in ALL
1:02
The key unmet needs in ALL
Anita Rijneveld • 17 Jun 2024
The addition of blinatumomab to prephase and consolidation therapy in adult B-ALL
2:57
The addition of blinatumomab to prephase and consolidation therapy in adult B-ALL
Anita Rijneveld • 17 Jun 2024
Incentive spirometry to prevent acute chest syndrome in adults with SCD
1:36
Incentive spirometry to prevent acute chest syndrome in adults with SCD
Anita Rijneveld • 20 Jun 2022
HOVON-100: clofarabine added to prephase and consolidation therapy in adult patients with ALL
1:30
HOVON-100: clofarabine added to prephase and consolidation therapy in adult patients with ALL
Anita Rijneveld • 20 Jun 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals